Viatris Inc at Goldman Sachs Global Healthcare Conference Transcript
Hi, everyone. Welcome to the afternoon sessions at our conference. My name is Nathan Rich, and I cover the U.S. generic space at Goldman. And I'm going back to the -- my colleague. We're very pleased to welcome Viatris for our next session. We're joined by the company's President, Rajiv Malik, CFO; Sanjeev Narula and Bill Szablewski, who runs Capital Markets and Investor Relations. Good to see all of you. I'm sorry that it had to be virtually. I'm sorry, Michael wasn't able since to make it as well. There's always next year, right?
Questions & Answers
So why don't we jump into the Q&A, if that's okay. And I wanted to start maybe, Rajiv, with you, a high level one on the strategy. At the Analyst Day earlier this year, you announced the divestiture of your biosimilar business results some other asset sales that you plan to do kind of reprioritize capital deployment towards share
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |